Elicio Therapeutics, Inc. announced on June 4, 2025, that it has secured $10 million in financing through a senior secured promissory note with existing investor GKCC, LLC. This funding is expected to extend the company's cash runway into the first quarter of 2026.
The promissory note bears an interest rate of up to 12.5% and matures on June 3, 2028, including a 24-month interest-only period. In connection with the financing, Elicio also issued warrants to GKCC, LLC to purchase an aggregate of 103,225 shares of common stock at an exercise price of $7.75 per share.
This transaction immediately strengthens Elicio's balance sheet, providing capital beyond the anticipated AMPLIFY-7P Phase 2 interim analysis expected in the third quarter of 2025. The financing offers flexibility to execute on near-term corporate and business development initiatives, supporting the continued advancement of ELI-002.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.